Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AMLAlexander E. Perl, Mark J. Levis, Giovanni Martinelli et al.|New England Journal of Medicine|2019Cited by 1.3k
Abstract CT184: Gilteritinib significantly prolongs overall survival in patients with <i>FLT3</i> -mutated ( <i>FLT3</i> mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trialAlexander E. Perl, Mark J. Levis, Giovanni Martinelli et al.|Cancer Research|2019Cited by 36
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsJan Philipp Bewersdorf, Amer M. Zeidan, Rory M. Shallis et al.|Annals of Hematology|2023Cited by 23
Chemoimmunotherapy and Withdrawal of Immunosupression for Monomorphic Posttransplant Lymphoproliferative DisordersNikolai A. Podoltsev, Dennis Cooper, Bingnan Zhang et al.|Clinical Lymphoma Myeloma & Leukemia|2013Cited by 8
Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous LeukemiaAbu‐Sayeef Mirza, Lohith Gowda, Bipin N. Savani et al.|Transplantation and Cellular Therapy|2022Cited by 0